Latest news
RLMD: Strong cash position and robust NDV-01 phase II results set stage for late-stage trials in 2026 - TradingViewTradingView · Thu, 06 Aug 2026 21:59:56 GMTBioVie’s stock sinks 50% as company uses composite endpoint to make case for Parkinson’s program - Fierce BiotechFierce Biotech · Thu, 06 Aug 2026 13:40:09 GMTSYRE: Strong Phase 2 results and $1.15B cash position support continued clinical progress - TradingViewTradingView · Tue, 04 Aug 2026 20:06:58 GMTAltimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder - Slideshow (NASDAQ:ALT) 2026-07-28 - Seeking AlphaSeeking Alpha · Tue, 28 Jul 2026 07:00:00 GMT